MetaCap

CytomX Therapeutics (CTMX) vs Lyell Immunopharma (LYEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lyell Immunopharma (LYEL) has outperformed CytomX Therapeutics (CTMX) over the past year, losing 27.9% versus a loss of 47.7%. Over five years, CTMX leads with a -69.9% price change compared with -92.6% for LYEL. CytomX Therapeutics is the larger company by market cap ($442.5 million vs $441.8 million), about 1.0 times the size, while Lyell Immunopharma is growing revenue faster (-41.0% vs -44.8%).

CytomX Therapeutics converts more of its revenue into profit, with a net margin of -22.8% versus -762355.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTMX-47.68%LYEL-27.86%
+110%+21%-69%
Nov 21, 20251 yearNov 20, 2026
CTMX-72.34%LYEL-93.62%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTMX versus LYEL key metrics
MetricCTMXLYEL
Share price$2.03$13.80
Market cap$442.55M$441.82M
1-day change-0.98%+1.62%
YTD return-52.35%-55.17%
1-year return-47.68%-27.86%
5-year return-69.93%-92.59%
EPS (TTM)$-0.51$-12.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$76.20M$36.00K
Revenue growth (YoY)-44.82%-40.98%
Net income (latest FY)$-17.37M$-274.45M
Operating margin-29.35%-748344.44%
Net margin-22.79%-762355.56%
52-week high$8.21$45.00
52-week low$1.87$7.20
Distance from 52-week high-75.27%-69.33%
Analyst consensusstrong_buybuy
Avg. price target upside+509.85%+172.68%
Average volume4.27M174.76K
Shares outstanding218.00M32.02M
Employees69161
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LYEL has outperformed CTMX by 19.8 percentage points over the past year.
  • CytomX Therapeutics is more profitable, keeping -22.8 cents of every revenue dollar as net income versus -762355.6 cents for Lyell Immunopharma.

About CytomX Therapeutics

CTMX stock →

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Lyell Immunopharma

LYEL stock →

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

CTMX vs LYEL FAQ

Which is bigger, CytomX Therapeutics or Lyell Immunopharma?

CytomX Therapeutics (CTMX) is larger, with a market capitalization of $442.55M compared with $441.82M for Lyell Immunopharma (LYEL).

Which stock has performed better over the past year, CTMX or LYEL?

LYEL returned -27.86% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.

Are CytomX Therapeutics and Lyell Immunopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons